Last year, FierceMedicalDevices debuted its list of top women in med tech. This year we'd like to make it even better. Please let us know who the most important women are in med tech, including medical devices and diagnostics.
Drugmakers such as Novartis and Sanofi long ago bowed out of the crop science field, bidding farewell to their units to focus their attention on pharma. But the way Bayer sees it, the area is an important piece of the life sciences puzzle.
Bayer CEO Marijn Dekkers bet that picking up Merck's consumer business last year would give his company a boost as it prepares to hive off its plastics unit and refocus on life sciences. Now Dekkers' gamble appears to be paying off, as the Leverkusen-based drugmaker beat analysts' estimates in Q2 with the help of its new consumer business and recent launches.
Last month, the FDA scheduled a September panel meeting to take a hard look at Bayer's controversial birth control device, Essure, after getting complaints of clinical trial fraud and serious side effects tied to the product. Now, the agency is facing more pushback from women campaigning against the device, who claim that regulators purposely selected the panel meeting date to coincide with a visit from the pope.
Bayer is gearing up to spin off its plastics unit and become a life-sciences-focused company, and as part of that prep, it's going on an investor roadshow to seek feedback on its plans.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
It may be too little too late. But now the FDA has signed off on the use of transvaginal ultrasound as a means of ensuring the proper placement of the Essure permanent birth control device within three months of its insertion.
Bayer has said it can pump an extra $400 million in revenue out of the OTC portfolio it acquired from Merck last year. And with that target in mind, new launches are on the agenda.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.
Whether animal health leader Zoetis receives any more buyout offers after Valeant's reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.